BB Biotech AG(BION.SW)— 品質與財務體檢
數據截至2026-11-16 — 每個交易日晚間更新。Closelook投資研究日記讀數,不構成評等或投資建議。
Closelook模組評分
60/100 綜合 · 7個模組 · 權重組合 general
- 估值71
- 品質95
- 成長16
- 資產負債表88
- 現金品質17
- 資本配置50
- 動能74
評分每個交易日晚間對全部追蹤範圍計算,並相對於追蹤範圍解讀——方法論詳見公司評分方法說明。
財務體檢 — 學術篩查指標
4/7皮奧特羅斯基F評分
涵蓋獲利能力、槓桿與營運效率的九項二元基本面強度檢查。
相關頁面: BION.SW圖表與概覽
FAQ · from the current data · as of 2026-11-16
Quick answers
BB Biotech AG的Closelook品質評分是多少?
綜合評分為60/100,涵蓋7個模組(截至2026-11-16):估值 71、品質 95、成長 16、資產負債表 88、現金品質 17、資本配置 50、動能 74。Closelook評分是研究日記讀數,不構成評等或投資建議。
BB Biotech AG的皮奧特羅斯基F評分是多少?
7分中的4分(截至2026-11-16)。F評分統計獲利能力、槓桿與營運效率方面的九項二元基本面強度訊號。
Related in the Closelooknet universe
then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.
- HALO Halozyme Therapeutics Incindustry
- ARGX.BR Argen-Xindustry
- UCB.BR UCB SAindustry
- ARGX argenx NV ADRindustry
- PTGX Protagonist Therapeutics Incindustry
- CORT Corcept Therapeutics Incorporatedindustry
- REPL Replimune Group Incindustry
- VCEL Vericel Corp Ordindustry
- VRDN Viridian Therapeutics Incindustry
- KOD Kodiak Sciences Incindustry
- XNCR Xencor Incindustry
- ADMA ADMA Biologics Incindustry
- MAZE Maze Therapeutics, Inc. Common Stockindustry
- REGN Regeneron Pharmaceuticals Incindustry
- ALK-B.CO ALK-Abelló A/Sindustry
- MEDCL.PA Medincell SAindustry
- NEU.AU Neuren Pharmaceuticals Ltdindustry
- RPRX Royalty Pharma Plcindustry
- ONC BeOne Medicines AGindustry
- RYTM Rhythm Pharmaceuticals Incindustry